Janus kinase inhibition in induction treatment of anti‐MDA5 juvenile dermatomyositis‐associated rapidly progressive interstitial lung disease
P. Ng, Archana Mopur, Daniel Yam Thiam Goh, Mahesh Babu Ramamurthy, Michael Teik Chung Lim, Lee Kean Lim, Pei Ling Ooi, Elizabeth Y. Ang
Abstract
Tofacitinib has an important role in pediatric rapidly progressive interstitial lung disease (ILD) associated with juvenile dermatomyositis (JDM), an otherwise potentially fatal condition. It may be useful in induction of remission and can be used safely to maintain remission. Serum ferritin and interleukin-18 are useful markers for tracking activity and response of JDM-associated ILD.
Topics & Concepts
MedicineJuvenile dermatomyositisInterstitial lung diseaseTofacitinibDermatomyositisJanus kinaseLungMDA5Internal medicineImmunologyCytokineChemistryBiochemistryRNA interferenceGeneRNARheumatoid arthritisInflammatory Myopathies and DermatomyositisInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisEosinophilic Disorders and Syndromes